Aref#d: 19369. A Phase II, Multi Centre Double Blind Randomised Placebo-Controlled Dose Escalation Pharmacokinetic and Pharmacodynamic Study of CK-1827452 in Patients with Stable Heart Failure (Clinical Trial)

Project Details

StatusFinished
Effective start/end date1/09/0728/02/13

Funding

  • Cytokinetics, Inc. (CK-1827452/CY1121): £11,452.00